Tisztelt Viktória!
Ennek a kérdésnek óriási irodalma van.
Legelőször a dohányzás elleni küzdelemben próbálkoztak:
Anabasine and Anatabine as Biomarkers for Tobacco Use during
Nicotine Replacement Therapy1
Peyton Jacob, III,2 Dorothy Hatsukami,
Herbert Severson, Sharon Hall, Lisa Yu, and
Neal L. Benowitz
In this study we determined urine concentration of the
tobacco alkaloids anabasine and anatabine, nicotine and
its metabolites cotinine, and nornicotine in 99 cigarette
smokers and 205 smokeless tobacco users. We also
investigated the possibility that anabasine and anatabine
can be used as biomarkers for tobacco use during
nicotine replacement therapy.
Urine samples and data on self-reported tobacco use
were obtained from subjects enrolled in tobacco cessation
programs. Urine concentrations of tobacco alkaloids and
metabolites were measured and correlated with selfreported
tobacco use. Concentrations of anabasine and
anatabine were used to validate abstinence in smokeless
tobacco users who used nicotine gum as part of the
therapy.
Correlations of alkaloid concentration with selfreported
tobacco use before treatment ranged from fair
to poor. In subjects abstaining from smokeless tobacco
but using nicotine gum, anabasine and anatabine levels
were below the cut-point of 2 ng/ml despite high
concentrations of nicotine and cotinine resulting from
nicotine gum use.
Anabasine and anatabine concentrations in urine can
be used to validate abstinence or measure the extent of
tobacco use in persons undergoing nicotine replacement
therapy."
Később kezdték el alkalmazni thyreoiditisben is (ezt én is javasoltam, de engedélyt nem kaptunk rá(!).
Milyen eredményt kaptak?
Anatabine supplementation decreases thyroglobulin
antibodies in patients with chronic lymphocytic
autoimmune (Hashimoto’s) thyroiditis: A randomized
controlled clinical trial
Lowell R. Schmeltz, MD, Thomas C. Blevins, MD, FACE, ECNU, FNLA,
Stephen L. Aronoff, MD, FACE, Kerem Ozer, MD,
Jonathan D. Leffert, MD, FACP, FACE, ECNU, Marc A. Goldberg, MD,
Barry S. Horowitz, MD, FACP, FACE; Richard H. Bertenshaw, MD,
Pedro Troya, MD, ECNU, Amy E. Cohen, MS, Ryan K. Lanier, PhD; and
Curtis Wright IV, MD, MPH
J Clin Endocrin Metab. First published ahead of print October 31, 2013 as doi:10.1210/jc.2013-2951
MA 01930 Clinical Trial Registration: clinicaltrials.gov Identifier: NCT01551498
Context: Hashimoto’s thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found
in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of
Hashimoto’s thyroiditis.
Objective: The effects of anatabine in patients with Hashimoto’s thyroiditis.
Design, Setting, Patients, and Intervention: Double-blind, randomized, placebo-controlled multisite
study.Atotal of 146 patients (70 treated with anatabine, and 76 placebo) completed the study.
Approximately 50% of patients in each group were on levothyroxine medication. Anatabine lozenges (9–24 mg/day) or placebo, each containing vitamins A and D3, were administered orally 3 times a day for three months.
Main Outcome Measures: Assessment of serum thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb). Safety was assessed though adverse events (AEs), clinical laboratory evaluations, and vital sign measurements.
Results: Anatabine treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those on placebo (p 0.027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb. Mean ( SD) TgAb values decreased by 46.2 ( 101.1) and 3.9 ( 83.9) WHO units for the anatabine and placebo groups,respectively. Significantly more patients had a 20% drop in TgAb in the anatabine than placebo group (p 0.023). Overall the anatabine supplement was safe and well tolerated, although significantly (p 0.05) more patients in the anatabine group reported AEs.
Conclusions: These results demonstrate an immunological effect of anatabine on TgAb levels.
Further studies are warranted (!) to dissect longer-term effects and possible actions of anatabine on the course of Hashimoto’s thyroiditis."
Összegezve: vannak biztató eredmények, de egyelőre itthon az engedélyezése, alkalmazása nem engedélyezett. Fontos azt is kiemelni, hogy a laboratóriumi lelet (antitest javulás) nem feltétlenül jelent gyógyulást.
Ezeket kellene vizsgálni, de......
Jó egészséget kívánok:
